Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review

被引：0
|
作者：
Zohreh Maghsoomi
Zahra Emami
Ramin Malboosbaf
Mojtaba Malek
Mohammad E. Khamseh
机构：
[1] Iran University of Medical Science (IUMS),Endocrine Research Center, Institute of Endocrinology and Metabolism
[2] Iran University of Medical Sciences (IUMS),Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism
来源：
BMC Cancer | / 21卷
关键词：
Peptide receptor radionuclide therapy; Radioiodine refractory-differentiated thyroid Cancer; Medullary thyroid carcinoma; Papillary thyroid carcinoma; Yttrium-90; 177Lu-DOTATATE; Indium-111; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Maghsoomi, Zohreh
    Emami, Zahra
    Malboosbaf, Ramin
    Malek, Mojtaba
    Khamseh, Mohammad E.
    BMC CANCER, 2021, 21 (01)
  • [2] Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Alfredo Campennì
    Salvatore A. Pignata
    Sergio Baldari
    Endocrine, 2015, 50 : 516 - 518
  • [3] Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Campenni, Alfredo
    Pignata, Salvatore A.
    Baldari, Sergio
    ENDOCRINE, 2015, 50 (02) : 516 - 518
  • [4] Advanced Radioiodine-refractory differentiated Thyroid Cancer
    Spitzweg, Christine
    Auernhammer, Christoph J.
    Geisler, Julia
    Boeck, Stefan
    Heinemann, Volker
    Bartenstein, Peter
    Goeke, Burkhard
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (03) : 168 - 171
  • [5] Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
    Kiyota, Naomi
    Robinson, Bruce
    Shah, Manisha
    Hoff, Ana O.
    Taylor, Matthew H.
    Li, Di
    Dutcus, Corina E.
    Lee, Eun Kyung
    Kim, Sung-Bae
    Tahara, Makoto
    THYROID, 2017, 27 (09) : 1135 - 1141
  • [6] Cabozantinib for radioiodine-refractory differentiated thyroid cancer
    Chiapponi, Costanza
    Hartmann, Milan J. M.
    Hescheler, Daniel A.
    Alakus, Hakan
    ONKOLOGE, 2021, 27 (12): : 1241 - 1242
  • [7] Targeted therapy in patients with radioiodine-refractory differentiated thyroid cancer (DTC)
    Herceg, Davorin
    Herceg, Gordana Horvatic
    PERIODICUM BIOLOGORUM, 2014, 116 (04) : 399 - 407
  • [8] Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
    Ovcaricek, Petra Petranovic
    Campenni, Alfredo
    de Keizer, Bart
    Deandreis, Desiree
    Kreissl, Michael C.
    Vrachimis, Alexis
    Tuncel, Murat
    Giovanella, Luca
    CANCERS, 2023, 15 (17)
  • [9] Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
    Brose, Marcia S.
    Capdevila, Jaume
    Elisei, Rossella
    Bastholt, Lars
    Fuehrer-Sakel, Dagmar
    Leboulleux, Sophie
    Sugitani, Iwao
    Taylor, Matthew H.
    Wang, Zhuoying
    Wirth, Lori J.
    Worden, Francis P.
    Bernard, John
    Caferra, Paolo
    Colzani, Raffaella M.
    Liu, Shiguang
    Schlumberger, Martin
    ENDOCRINE-RELATED CANCER, 2024, 31 (08)
  • [10] Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis
    Ji, Xiaoyu
    Liang, Weili
    Lv, Guixu
    Ding, Changyuan
    Lai, Hong
    Li, Luchuan
    Zeng, Qingdong
    Lv, Bin
    Sheng, Lei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345